EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes ( TTT1 )—An International Phase 3 Clinical Trial

Joseph G Timmons iD, Husam Ghanim iD, James G Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A Batra, Robert S Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R Petrie, Paresh Dandona

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71076 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Joseph G Timmons und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glucagon-Like Peptides, Hypoglycemic Agents, Glucosides. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breakthrough T1D, JDRF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis. We designed the first Phase 3 clinical trial to assess the efficacy and safety of adding a Glucagon‐Like Peptide 1 receptor agonist (GLP‐1RA) and a Sodium‐Glucose Co‐transporter (SGLT2) Inhibitor to insulin therapy in overweight and obese adults with T1D and glycaemia above target (HbA1c 7.5%–11.0% inclusive) (NCT03899402). Materials and Methods In Period 1, participants are randomized 2:1 (open label) for 26 weeks to semaglutide and insulin (uptitrated to 1.0 mg weekly) or standard insulin therapy. In Period 2, those randomized to semaglutide and insulin in Period 1 are further randomized (double‐blind) for 26 weeks to dapagliflozin (10 mg daily) or placebo, in addition to semaglutide. The primary objective is to compare change in HbA1c on ‘triple therapy’ (dapagliflozin, semaglutide and insulin) with ‘dual therapy’ (placebo, semaglutide and insulin). Secondary objectives include comparisons of triple therapy with standard insulin therapy and dual therapy (semaglutide and insulin) with standard insulin therapy. Safety outcomes include hypoglycaemia and ketosis. A sample size recalculation during the trial based on analysis of masked data revised the original recruitment target from 114 to 82 participants.

Conclusion

The TTT1 trial will provide clinically useful information on combination adjunct therapy in the treatment of T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Glucagon-Like PeptidesHypoglycemic AgentsGlucosidesInsulinBenzhydryl CompoundsHumansSemaglutideDrug Therapy, CombinationAdultFemaleMaleDouble-Blind MethodGlycated HemoglobinMiddle AgedSodium-Glucose Transporter 2 InhibitorsBlood GlucoseTreatment OutcomeHypoglycemiaObesity

Stichwörter der Autor:innen

adjunct therapyadjunctive therapycombination therapy dapagliflozinketosissemaglutidetype 1 diabetes

Substanzen

SemaglutidedapagliflozinGlucagon-Like PeptidesHypoglycemic AgentsGlucosidesInsulinBenzhydryl CompoundsGlycated HemoglobinSodium-Glucose Transporter 2 InhibitorsBlood Glucose

Autor:innen und Institutionen

  • School of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • State University of New York at Buffalo, Buffalo, New York, USA.
  • School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Robertson Centre for Biostatistics/Glasgow Clinical Trials Unit, School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, UK.
  • Department of Research and Innovation, NHS Greater Glasgow and Clyde, Gartnavel Royal Hospital, Glasgow, UK.
  • University of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille, France.

ORCID-Profile: Joseph G Timmons, Husam Ghanim

Förderung

  • Breakthrough T1D
  • JDRF

Zitieren

APA

Timmons, J. G., Ghanim, H., Boyle, J. G., Greenlaw, N., Chaudhuri, A., Batra, M. A., Lindsay, R. S., Jolly, L., Bonner, C., McConnachie, A., Petrie, J. R., & Dandona, P. (2026). Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes ( TTT1 )—An International Phase 3 Clinical Trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71076

Vancouver

Timmons JG, Ghanim H, Boyle JG, Greenlaw N, Chaudhuri A, Batra MA, et al. Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes ( TTT1 )—An International Phase 3 Clinical Trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71076

BibTeX
@article{Timmons2026,
  author = {Timmons, Joseph G and Ghanim, Husam and Boyle, James G and Greenlaw, Nicola and Chaudhuri, Ajay and Batra, Manav A and Lindsay, Robert S and Jolly, Lisa and Bonner, Caroline and McConnachie, Alex and Petrie, John R and Dandona, Paresh},
  title = {Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes ( TTT1 )—An International Phase 3 Clinical Trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71076}
}
Kostenlos starten →